1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Macrocure's CureXcell Phase III Leg Ulcer Study Futile

 
• By Alexandra Shimmings

Israeli stem cell company Macrocure's lead wound-healing product CureXcell has stumbled in a US Phase III study in venous leg ulcers (VLU) – with a futility analysis revealing that it is not expected to meet its primary endpoint. Shares in the firm dropped by 72% to £3.33 in early trading on Nasdaq on Aug. 20, from a previous day's close of $12.05.

Israeli stem cell company Macrocure's lead wound-healing product CureXcell has stumbled in a US Phase III study in venous leg ulcers (VLU) – with a futility analysis revealing that it is not expected to meet its primary endpoint. Shares in the firm dropped by 72% to £3.33 in early trading on Nasdaq on Aug. 20, from a previous day's close of $12.05.

The cell-based product, which is already on the Israeli market for wound healing, consists of human activated white blood cells which are supposed to help the healing process to stimulate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

More from Therapy Areas

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback